Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

2lherp®

Phase 3

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Herpes SimplexRecruiting

Herpes SimplexPhase 3

Recruiting

Timeline

Expected Milestones

Q1 2027

ApprovedRecruiting

Herpes Simplex

NCT04065971

Clinical

Trials by Indication[1]

Herpes Simplex1 trial

Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy of 2LHERP® in Patients With Recurrent Orofacial Herpes Infections.

Recruiting·LLabo'Life·Approved·NCT04065971·140 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for 2lherp®. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for 2lherp®. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Labo'Life company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: LLabo'Life

Related News